Pulmonary function and clinical course in patients with cystic fibrosis after pulmonary colonization with Pseudomonas aeruginosa
- PMID: 2109790
- DOI: 10.1016/s0022-3476(05)82653-8
Pulmonary function and clinical course in patients with cystic fibrosis after pulmonary colonization with Pseudomonas aeruginosa
Abstract
To evaluate the relationship between Pseudomonas aeruginosa colonization and the development of lung disease, we studied 895 patients who attended our cystic fibrosis clinic between 1975 and 1988. The prevalence of P. aeruginosa colonization was 82%. Patients who acquired P. aeruginosa in the first year of life had a similar 10-year survival rate (85%) to that in patients who were colonized between the ages of 1 and 7 years (87%), and to that in patients colonized after the age of 7 years (78%). One year before colonization, mean age, forced expiratory volume in 1 second (FEV1), forced vital capacity, and forced expiratory flow in the mid-expiratory phase were similar to those in a group of patients who remained free of P. aeruginosa. No significant change in pulmonary function variables could be demonstrated 1 year and 2 years after the colonization. The rate and duration of hospitalization did not increase in the years after P. aeruginosa colonization compared with the years before colonization. By the age of 7 years, the mean percentage of predicted FEV1 was lower by 10% in patients who were already colonized by P. aeruginosa compared with those who were not colonized (p less than 0.01). A similar reduction in FEV1 was observed at all ages from 7 to 35 years, but no precipitate rate of decline in FEV1 could be associated with P. aeruginosa colonization. We conclude that although P. aeruginosa colonization is associated with 10% lower lung function, it does not cause an immediate and rapid reduction, as has been previously reported. The clinical course and the pulmonary deterioration in cystic fibrosis after P. aeruginosa colonization is a gradual and variable process.
Similar articles
-
Respiratory tract colonization with Pseudomonas aeruginosa in cystic fibrosis: correlations between anti-Pseudomonas aeruginosa antibody levels and pulmonary function.Pediatr Pulmonol. 1991;10(2):92-100. doi: 10.1002/ppul.1950100210. Pediatr Pulmonol. 1991. PMID: 1903199
-
Effects of pseudomonas aeruginosa colonization on lung function and anthropometric variables in children with cystic fibrosis.Pediatr Pulmonol. 1995 Jan;19(1):10-5. doi: 10.1002/ppul.1950190103. Pediatr Pulmonol. 1995. PMID: 7675552
-
Pulmonary evolution of cystic fibrosis patients colonized by Pseudomonas aeruginosa and/or Burkholderia cepacia.Eur J Pediatr. 1998 May;157(5):427-31. doi: 10.1007/s004310050844. Eur J Pediatr. 1998. PMID: 9625343
-
Infections with Pseudomonas aeruginosa in patients with cystic fibrosis.Behring Inst Mitt. 1997 Feb;(98):249-55. Behring Inst Mitt. 1997. PMID: 9382747 Review.
-
Chemistry and biology of the alginate of mucoid strains of Pseudomonas aeruginosa in cystic fibrosis.Mol Aspects Med. 1988;10(1):1-91. doi: 10.1016/0098-2997(88)90002-7. Mol Aspects Med. 1988. PMID: 3129631 Review. No abstract available.
Cited by
-
Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa.Paediatr Drugs. 2007;9 Suppl 1:11-20. doi: 10.2165/00148581-200709001-00003. Paediatr Drugs. 2007. PMID: 17536871 Clinical Trial.
-
Comparison of the sensitivity of culture, PCR and quantitative real-time PCR for the detection of Pseudomonas aeruginosa in sputum of cystic fibrosis patients.BMC Microbiol. 2009 Nov 29;9:244. doi: 10.1186/1471-2180-9-244. BMC Microbiol. 2009. PMID: 19943966 Free PMC article.
-
Characterization of Hypermutator Pseudomonas aeruginosa Isolates from Patients with Cystic Fibrosis in Australia.Antimicrob Agents Chemother. 2019 Mar 27;63(4):e02538-18. doi: 10.1128/AAC.02538-18. Print 2019 Apr. Antimicrob Agents Chemother. 2019. PMID: 30745381 Free PMC article.
-
Impact of Pseudomonas aeruginosa Infection on Patients with Chronic Inflammatory Airway Diseases.J Clin Med. 2020 Nov 24;9(12):3800. doi: 10.3390/jcm9123800. J Clin Med. 2020. PMID: 33255354 Free PMC article. Review.
-
Heterogenous Susceptibility to R-Pyocins in Populations of Pseudomonas aeruginosa Sourced from Cystic Fibrosis Lungs.mBio. 2021 May 4;12(3):e00458-21. doi: 10.1128/mBio.00458-21. mBio. 2021. PMID: 33947755 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical